ClinicalTrials.gov
public full text
Public Domain
Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia
An observational study assessing the impact of anti-citrullinated antibody (ACPA) in rheumatoid arthritis (RA) participants who have received abatacept or tumour necrosis factor inhibitors (TNFi) from the Optimising Patient outcome in Australian rheumatoLogy (OPAL) registry
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Observational Study of Tocilizumab in Participants With Rheumatoid Arthritis in Australia#840111
- Real-life Experience of Tofacitinib in Patients With Treatment-Resistant Rheumatoid Arthritis#1075367
- COVID-SErology in Rheumatoid Arthritis (COVID-19)#1030116
- Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.#1010611
- Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF#1183583
Record · ID 1410384
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive